LIST OF FIGURES for the Pharmaceuticals Report

Figure 3.1: Global Pharmaceutical Market Size & Growth Rate, 2000 - 2005
Figure 3.2: Regional nature of the Pharmaceutical Industry - 2000 & 2005
Figure 3.3: Major Therapeutic Segments of the Industry- 2005
Figure 3.4: Merger & Acquisition activity by year, 1995 -2005
Figure 3.5: Global Pharmaceutical Outsourcing Market Size, 2001 - 2005
Figure 3.6: Pharmaceutical R&D Expenditure, 1990 - 2004
Figure 4.1: Percentage of population aged 0-24 as a percentage of total population (2000-2025)
Figure 4.2: Percentage of population aged 55 & above as a percentage of total population (2000-2025)
Figure 4.3: Percentage distribution of DALYs by cause - Global scenario (2000-2030)
Figure 4.4: Healthcare expenditure as a % of GDP
Figure 4.5: Pharmaceutical expenditure as a % of total healthcare expenditure (1993-2003)
Figure 4.6: Biotech vs pharma growth (2000 - 2004)
Figure 5.1: Number of new drugs approved and R&D spend (2001-2005)
Figure 5.2: Patent expiries by value (2005-2010)
Figure 5.3: Global sales of Prozac (2000-2003)
Figure 7.0: Major market share of the global pharmaceutical industry 2005
Figure 7.1: GDP growth rate of the US, 2001-2005
Figure 7.2: Pharmaceutical market in the USA, 2001-2005
Figure7.3: Pharmaceutical market segmentation in the US, 2005
Figure 7.4: Pharmaceutical market share by value in the US, 2005
Figure 7.5: GDP growth rate of Japan, 2001-2005
Figure 7.6: Pharmaceutical market in Japan, 2001-2005
Figure 7.7: Pharmaceutical market segmentation in Japan, 2005
Figure 7.8: Pharmaceutical market in Europe, 2001-2005
Figure 7.9: Major Pharmaceutical markets in Europe, 2005
Figure 7.10: GDP growth rate of the UK, 2001-2005
Figure 7.11: Pharmaceutical market in the UK, 2001-2005
Figure 7.12: Pharmaceutical market segmentation in the UK,
Figure: 7.13: GDP growth rate of Mexico, 2001-2005
Figure 7.14: Pharmaceutical market in Mexico, 2001-2005
Figure 7.15: Pharmaceutical market segmentation in Mexico, 2005
Figure 7.16: GDP growth rate of Brazil, 2001-2005
Figure 7.17: Pharmaceutical market in Brazil, 2001-2005
Figure 7.18: Pharmaceutical market segmentation in Brazil, 2005
Figure 7.19: GDP growth rate of China, 2001-2005
Figure 7.20: Pharmaceutical market in China, 2001-2005
Figure 8.1: Pfizer Price Movement in 2005 (NYSE)
Figure 8.2: Johnson & Johnson Price Movement in 2005 (NYSE)
Figure 8.3: GlaxoSmithKline ADR Price Movement in 2005 (NYSE)
Figure 8.4: Sanofi-Aventis ADR Price Movement in 2005 (NYSE)
Figure 8.5: Novartis Price Movement in 2005(Swiss Exchange)
Figure 8.6: Roche Price Movement in 2005 (Swiss Exchange)
Figure 8.7: AstraZeneca ADR Price Movement in 2005 (NYSE)
Figure 8.8: Merck Price Movement in 2005 (NYSE)
Figure 8.9: BMS Price Movement in 2005 (NYSE)
Figure 8.10: Wyeth Price Movement in 2005 (NYSE)
Chart 9.1: EU Centralized Drug Approval Procedure
Chart 9.2: EU decentralized Drug Approval Procedure
Figure 10.1: Generics retail market estimates (USDbn) - 2005 & 2010
Figure 10.2: Pharmaceutical M&A 2005
Figure 10.2: Pharmaceutical M&A as a % of total healthcare M&A in terms of number of deals and deal value - (2000-2005)
Figure 10.3: Number of Pharmaceutical M&A - (2001 - 2005)
Figure 10.4: Deal value of Pharmaceutical M&A - (2001 - 2005)
Figure 10.5: Net Sales of Sandoz Including and Excluding Acquisitions (2004 & 2005)